drugset / Trial / NCT07725380
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Phase 1/2
Recruiting
74 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Healx USA, Inc · collabNational Pediatric Cancer Foundation · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.
Timeline
- Start
- 2026-07-15
- Primary completion
- 2031-08
- Completion
- 2031-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Domatinostat | Small molecule | — | — |
| Subject | Sirolimus | Small molecule | — | — |